CKX8 Antibody

What is Cytokeratin 8 and why is it significant in biomedical research?

Cytokeratin 8 (CK8) is a type II intermediate filament protein with a molecular weight of approximately 52-54 kDa. It belongs to the family of high molecular weight (HMW) B-type cytokeratins and is primarily expressed in non-squamous epithelium . CK8, along with CK19, helps link the contractile apparatus to dystrophin at the costameres of striated muscle .

CK8's significance stems from its expression pattern and role in pathological conditions. It serves as an important marker for adenocarcinomas and ductal carcinomas, making it valuable in cancer diagnostics and research . Additionally, CK8 has been identified as a tumor antigen, with antibodies against it found in the serum of cancer patients . In pulmonary fibrosis, CK8:anti-CK8 immune complexes have been detected, suggesting a role in disease pathogenesis .

What types of CK8 antibodies are available for research applications?

Researchers have access to several types of CK8 antibodies, each with specific characteristics suitable for different applications:

• Monoclonal Antibodies: These provide high specificity by recognizing a single epitope on CK8. Examples include mouse monoclonal antibody [5D3] (ab17139), which targets both Cytokeratin 8 and 18 and has been validated for multiple applications .

• Polyclonal Antibodies: These recognize multiple epitopes on CK8, often providing higher sensitivity. The CK-8 Polyclonal Antibody (E-AB-70236) is rabbit-derived and has been verified for use with human, mouse, and rat samples .

• Human-derived Antibodies: These include antibodies like AE6F4, established from in vitro immunization of human peripheral blood lymphocytes with lung adenocarcinoma cells. These can recognize CK8 as well as other related antigens .

How should researchers select the appropriate CK8 antibody for their experiments?

When selecting a CK8 antibody, researchers should consider several factors:

• Experimental Application: Different antibodies perform optimally in specific applications. Verify that the antibody has been validated for your intended use (Western blot, IHC, flow cytometry, etc.) .

• Species Reactivity: Confirm that the antibody recognizes CK8 in your species of interest. Some antibodies are species-specific, while others cross-react with multiple species. For example, the CK-8 Polyclonal Antibody (E-AB-70236) reacts with human, mouse, and rat samples .

• Epitope Recognition: Consider which region of CK8 the antibody targets, particularly if studying modified forms or specific domains of the protein.

• Clonality: Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies may provide better sensitivity by recognizing multiple epitopes.

• Verified Samples: Check if the antibody has been tested on your specific sample types. For example, some antibodies have been verified on cell lines like HepG2, A549, and MCF-7, and tissues like human colon and mouse lung .

How can CK8 antibodies be used to study pulmonary fibrosis pathogenesis?

CK8 antibodies have provided valuable insights into pulmonary fibrosis pathogenesis through the identification and characterization of immune complexes:

• Detection of Circulating Immune Complexes: Western immunoblot techniques using anti-CK8 antibodies can demonstrate the presence of CK8:anti-CK8 immune complexes in patient sera. This was the first study to clarify the antigen of circulating immune complexes in idiopathic pulmonary fibrosis (IPF) .

• Quantitative Assessment: ELISA methods can be established to quantitate these immune complexes. In one study, high CK8:anti-CK8 antibody complexes were found in 29.0% of patients with IPF and pulmonary fibrosis associated with collagen vascular disorders (PF-CVD) .

• Mechanistic Studies: The presence of these immune complexes suggests they may play a role in lung injury processes. Researchers can investigate how these complexes form, deposit in tissues, and potentially trigger inflammatory responses .

• Therapeutic Target Identification: Understanding the role of CK8:anti-CK8 immune complexes could lead to novel therapeutic approaches targeting their formation or deposition.

What is the role of CK8 as a tumor antigen and how can antibodies help investigate this?

CK8 has been identified as a tumor antigen with potential implications for cancer diagnostics and therapeutics:

• Autoantibody Detection: Techniques like Autoantibody Mediated Identification of Antigens (AMIDA) have identified CK8 as a tumor antigen. Elevated serum levels of CK8-specific antibodies have been found in patients with head and neck cancer .

• Specificity Assessment: Studies have shown that CK8 serum reactivity is 3.2 times higher in patients with benign disease (16%) and 2.4 times higher in patients with carcinomas (12%) compared to healthy donors. Interestingly, this reactivity correlates more with disease localization than with whether the disease is malignant or benign .

• Antigenic Modifications: In non-small-cell lung cancer (NSCLC) cell lines, CK8 with higher molecular weight than normal has been observed. These modified forms contain antigenic epitopes of CA19-9, suggesting CK8 can serve as a carrier protein for tumor-associated carbohydrate antigens .

• Biomarker Potential: While CK8-specific antibodies alone may not be sufficient for differentiating between carcinomas and benign diseases, they could be valuable as part of a panel of biomarkers .

What are the optimal protocols for using CK8 antibodies in Western blotting?

For successful Western blotting with CK8 antibodies, researchers should follow these methodological guidelines:

• Sample Preparation:

  • Lyse cells or homogenize tissues in buffer containing protease inhibitors

  • Clarify lysates by centrifugation to remove debris

  • Quantify protein concentration using methods like BCA assay

• Gel Electrophoresis:

  • Load 20-50 μg of total protein per lane

  • Use 8-12% SDS-PAGE gels for optimal resolution of CK8 (54 kDa)

• Transfer and Blocking:

  • Transfer proteins to PVDF or nitrocellulose membranes

  • Block with 5% non-fat dry milk in PBS (PBSM blocking buffer) or similar

• Antibody Incubation:

  • Primary CK8 antibody: Dilute 1:500-1:2000 in blocking buffer

  • Incubate overnight at 4°C or 1-2 hours at room temperature

  • Secondary antibody: Follow manufacturer's recommendations (typically 1:1000-1:5000)

  • Include 0.05% Tween-20 in wash buffers (PBST)

• Detection and Analysis:

  • Use appropriate detection system (chemiluminescence or fluorescence)

  • Expected band size for CK8 is approximately 54 kDa

  • Be aware that modified forms of CK8 may appear at different molecular weights

How can ELISA be optimized for detection of CK8 or CK8:anti-CK8 immune complexes?

ELISA methods can be optimized for quantitative detection of CK8 or related immune complexes:

• Sandwich ELISA Design:

  • For detecting CK8, coat plates with a capture antibody specific for one epitope of CK8

  • Detect bound CK8 with a detection antibody recognizing a different epitope

  • For immune complexes, use anti-human IgG as the capture antibody and anti-CK8 as the detection antibody

• Kinetic ELISA Approach:

  • Monitor reaction rate during the linear phase when product formation is directly proportional to analyte concentration

  • Ensure substrate concentration is saturating and enzymatic catalysis operates in steady-state conditions

  • This approach can provide more accurate quantitation than endpoint measurements

• Buffer Optimization:

  • Use PBS (phosphate-buffered saline, pH 7.4) as the base buffer

  • Include 0.05% Tween-20 (PBST) in wash buffers

  • Block with appropriate agents such as 5% non-fat dry milk in PBS

• Control and Calibration:

  • Establish a cutoff value based on healthy volunteer samples

  • Include standard curves using recombinant CK8 or purified immune complexes

  • Include positive and negative controls in each assay

What molecular modifications of CK8 have been observed in cancer, and how can they be detected?

CK8 can undergo several modifications in cancer cells that alter its properties and recognition by antibodies:

• Higher Molecular Weight Forms:

  • CK8 with higher molecular weight than recombinant CK8 has been observed in NSCLC cell lines

  • These modified forms were demonstrated in two of eight NSCLC cell lines studied

• Glycosylation Changes:

  • The higher molecular weight CK8 found in cancer cells contains tumor-associated carbohydrate antigens like CA19-9

  • This suggests that CK8 can be glycosylated with cancer-specific carbohydrate structures

• Detection Methods:

  • Western blot analysis using anti-CK8 antibodies can identify size differences

  • Co-immunoprecipitation with antibodies against both CK8 and carbohydrate antigens can confirm modifications

  • Mass spectrometry can provide detailed characterization of specific modifications

• Functional Implications:

  • These higher molecular weight forms of CK8 may play a role in cancer invasion or metastasis

  • The modifications could alter CK8's interactions with other cellular components

How can multiplex immunoassays be developed using CK8 antibodies?

Multiplex approaches incorporating CK8 antibodies can provide comprehensive analysis of samples:

• Panel Development:

  • Combine CK8 antibodies with antibodies against other cytokeratins (CK18, CK19) and epithelial markers

  • Include markers for specific cancer types or cellular states for comprehensive profiling

• Multiparameter Flow Cytometry:

  • Conjugate CK8 antibodies to spectrally distinct fluorophores

  • Combine with antibodies against other markers for simultaneous multiparameter analysis

  • Particularly useful for detecting circulating tumor cells or analyzing tumor heterogeneity

• Multiplex Immunohistochemistry:

  • Use sequential staining protocols with CK8 antibodies and other markers

  • Employ spectral imaging systems to resolve multiple fluorophores

  • This allows visualization of multiple markers in the spatial context of tissue architecture

• Multiplex ELISA Systems:

  • Develop bead-based multiplex assays for simultaneous detection of CK8 and other proteins

  • This approach can be particularly valuable for serum biomarker screening

How should researchers interpret conflicting CK8 antibody data?

When faced with discrepancies in CK8 antibody results, researchers should systematically investigate potential causes:

What are common issues in CK8 immunohistochemistry and how can they be resolved?

Immunohistochemistry with CK8 antibodies can present several challenges:

• Weak or Absent Staining:

  • Problem: Insufficient antigen retrieval or antibody concentration

  • Solution: Optimize antigen retrieval conditions (try both citrate and EDTA buffers); titrate antibody concentration; increase incubation time

• High Background:

  • Problem: Insufficient blocking or non-specific binding

  • Solution: Increase blocking time or concentration; include additional blocking agents like normal serum; optimize washing steps

• Non-specific Staining:

  • Problem: Cross-reactivity with other cytokeratins or non-specific binding

  • Solution: Select more specific antibodies; include appropriate controls; increase antibody dilution

• Tissue-Specific Issues:

  • Problem: Fixation artifacts or tissue-specific factors affecting staining

  • Solution: Standardize fixation protocols; optimize protocols for specific tissue types

• Inconsistent Results:

  • Problem: Variability in tissue processing or staining conditions

  • Solution: Standardize all steps of the protocol; include positive and negative controls with each batch

What might cause variations in CK8 molecular weight observations in Western blotting?

Variations in observed CK8 molecular weight can result from several factors:

• Post-Translational Modifications:

  • Phosphorylation, glycosylation, or other modifications can alter CK8 mobility in gels

  • Cancer cells may express CK8 with tumor-associated carbohydrate antigens, resulting in higher molecular weight forms

• Protein Degradation:

  • Insufficient protease inhibition during sample preparation can cause partial degradation

  • This can result in lower molecular weight bands being detected

• Sample Preparation Effects:

  • Different lysis buffers or denaturation conditions can affect protein migration

  • Cross-linking agents in certain fixatives can alter apparent molecular weight

• Gel Concentration Impact:

  • The percentage of acrylamide in gels affects protein migration patterns

  • Standardize gel conditions for consistent results

• Interpretation Guidelines:

  • The expected 54 kDa band for CK8 may appear at slightly different positions depending on the experimental conditions

  • Multiple bands may represent different isoforms or modified versions of CK8

How can researchers minimize non-specific binding of CK8 antibodies?

Reducing non-specific binding is crucial for generating clean, interpretable results:

• Blocking Optimization:

  • Use appropriate blocking buffers such as 5% non-fat dry milk in PBS

  • Include 0.05% Tween-20 in wash buffers (PBST)

  • Consider including additional blocking agents for problematic samples

• Antibody Dilution Optimization:

  • Test a range of antibody dilutions to find the optimal concentration

  • For Western blotting, typical dilutions range from 1:500-1:2000

  • For IHC, typical dilutions range from 1:200-1:800

• Sample Pre-Treatment:

  • Pre-clear samples if high background persists

  • For flow cytometry, include 10% normal goat serum and 0.3M glycine to block non-specific protein-protein interactions

• Secondary Antibody Selection:

  • Use pre-adsorbed secondary antibodies to minimize cross-reactivity

  • Include isotype controls to identify potential non-specific binding

• Protocol Optimization:

  • Increase number and duration of wash steps

  • Optimize incubation temperature and time

  • Ensure all buffers are freshly prepared and at the correct pH

How might CK8 antibodies contribute to liquid biopsy development?

CK8 antibodies hold promise for advancing liquid biopsy applications in cancer diagnostics:

• Circulating Tumor Cell (CTC) Detection:

  • CK8 antibodies can help identify epithelial-derived CTCs in blood samples

  • When combined with other markers, they can enhance CTC capture and characterization

• Circulating Protein Biomarkers:

  • Detection of CK8 or CK8:anti-CK8 immune complexes in serum as potential biomarkers

  • These could aid in early detection, prognosis determination, or treatment response monitoring

• Exosome Analysis:

  • CK8 antibodies might be used to identify and capture exosomes from epithelial cancer cells

  • This could provide insights into tumor communication and metastatic processes

• Methodological Advances:

  • Development of high-sensitivity assays for detecting low levels of CK8 in blood

  • Automation and standardization of detection protocols for clinical implementation

What is the potential of CK8 antibodies in therapeutic applications?

Beyond their diagnostic utility, CK8 antibodies may have therapeutic applications:

• Targeted Drug Delivery:

  • CK8 antibodies conjugated to therapeutic agents could deliver drugs specifically to CK8-expressing cancer cells

  • This approach might be particularly relevant for adenocarcinomas that consistently express CK8

• Immune Complex Disruption:

  • In conditions like pulmonary fibrosis where CK8:anti-CK8 immune complexes contribute to pathology, therapeutic strategies to prevent complex formation or deposition might be beneficial

• Chimeric Antigen Receptor (CAR) T-Cell Therapy:

  • CK8 antibody-derived single-chain variable fragments could be incorporated into CAR-T cells

  • This could enable targeting of internal antigens that become exposed in cancer cells

• Antibody-Dependent Cellular Cytotoxicity:

  • Engineered CK8 antibodies might be developed to enhance immune system recognition and elimination of cancer cells expressing modified CK8

How could advanced imaging technologies enhance CK8 antibody applications?

Emerging imaging technologies can expand the utility of CK8 antibodies in research and diagnostics:

• Super-Resolution Microscopy:

  • Techniques like STORM or STED can reveal nanoscale organization of CK8 filaments

  • This could provide insights into cytoskeletal reorganization in cancer cells

• Multiplexed Imaging:

  • Methods like cyclic immunofluorescence or imaging mass cytometry allow visualization of CK8 alongside numerous other markers

  • This enables comprehensive characterization of tissue architecture and cellular states

• Intravital Imaging:

  • In vivo imaging using CK8 antibodies could track tumor development in animal models

  • This approach could provide dynamic information about metastatic processes

• Artificial Intelligence Integration:

  • AI-based image analysis of CK8 staining patterns could identify subtle features associated with disease progression or treatment response

  • This could enhance diagnostic accuracy and prognostic assessment